News
Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business
Omnicell, Inc., a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously...
News
Siegfried to Acquire Two Pharmaceutical Manufacturing Sites from Novartis in Spain
Siegfried has signed binding agreements with Novartis regarding the acquisition of two pharmaceutical manufacturing sites in Spain. With this acquisition, Siegfried will significantly enhance its...
News
BMS Announces Update on CheckMate -915 Evaluating Opdivo Plus Yervoy Versus Opdivo in Resected High-Risk Melanoma Patients
Bristol Myers Squibb announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo...
News
EMA starts first rolling review of a COVID-19 vaccine in the EU
EMA’s human medicines committee (CHMP) has started the first ‘rolling review’ of a COVID-19 vaccine, which is being developed by the company AstraZeneca in collaboration...
News
AstraZeneca: COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
A...
News
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced that it has established a new...
News
Dr. Reddy’s Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market
Dr. Reddy’s Laboratories Ltd. announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.